Klox Technologies
Klox Technologies Inc. is a private regenerative medicine company, advancing the development of its proprietary Fluorescent Light Energy (FLE) platform, also known as Fluorescence Biomodulation, for specific skin/soft tissue conditions and diseases. Our platform has shown to impact cellular signaling pathways, which stimulate the skin’s own biological processes and repair mechanisms. At our core we research, develop, and partner our proprietary products for a growing population that is seeking a high degree of clinical effectiveness, while being less invasive, safe and cost effective.
Explore our Technology
Klox’s products are applied topically to the skin and are subsequently illuminated by an LED activator for a short period of under 10 minutes. The topical is not required to be metabolized or internalized by the skin prior to the illumination.
The LED activator’s emission interacts with specialized molecules embedded within Klox’s topical product to generate a unique emission of fluorescent light energy. Klox utilizes this unique emission to target diseases and conditions affecting the skin and soft tissues.
Fluorescent light energy is a form of photobiomodulation, which utilizes fluorescence energy to induce multiple transduction pathways that can modulate biological processes through the activation of photoacceptors found within many different cell and tissue types. Read more.
About Us
Klox Technologies Inc. is a private regenerative medicine company, advancing the development of its FLE platform, also known as Fluorescence Biomodulation, for specific skin/soft tissue conditions and diseases. We believe in providing healthcare professionals with novel and effective treatment solutions, which in turn allow patients to experience positive results without extensive side effects or high costs associated with existing standard of care treatments.
Trusted Collaborators
At Klox, we always strive to build and invest in our science, technology, and engineering expertise. To challenge the conventions of the industry, we extend our capabilities by collaborating with leading professionals and cutting-edge scientific facilities, wherever they may be. Our extended network is critical for maintaining vitality and scientific rigor in our mission to bring out unique product offerings to patients in need.
News & Events
December 12, 2019
Vetoquinol and Klox Technologies Announce Global Animal Health Collaboration Agreement – Lure, France
December 12, 2019
FDA Grants Device Designation Status for Klox’s LumiHeal System – Laval, Quebec
October 29, 2019
October 27-29, 2019
Targeting Mitochondria Congress – Berlin, Germany
October 22-23, 2019
The International Scar Club Meeting – Montpellier, France
October 8, 2019
Klox Technologies Inc. announces the appointment of Mr. Domenic Serafino and Dr. Richard Markoff to its board of directors – See Full Press Release here
October 4, 2019
Klox Technologies Inc. Announces Completion of the Acquisition of FB Dermatology – See Full Press Release here
September 26-28, 2019
The SICPRE Conference (Italian Society of Plastic Aesthetic and Reconstructive Surgery) – Palermo, Italy
September 23-25, 2019
The MedTech Conference – Boston, United States
August 30, 2019
Publication in Science Direct – Interest of photobiomodulation in the management of acute second-degree burns
August 19-22, 2019
Military Health System Research Symposium – Florida, United States
August 13, 2019
Publication in the peer-reviewed Journal of Veterinary Dermatology – Fluorescence biomodulation in the management of canine interdigital pyoderma cases: a prospective, single‐blinded, randomized and controlled clinical study
June 10-15, 2019
World Congress of Dermatology – Milan, Italy
June 5-7, 2019
European Wound Management Association – Gothenburg, Sweden
May 16-17, 2019
VetCon – Cork, Ireland
May 3-4, 2019
The European Society of Lymphology Meeting – Brussels, Belgium
March 20-21, 2019
Medical Technology Enterprise Consortium – South Carolina, USA
March 15-17, 2019
La Chirurgia Estetica– Florence, Italy
March 8, 2019
Publication in the SPIE Photonics West 2019 Conference Proceedings – Management of all three phases of wound healing through the induction of fluorescence biomodulation using fluorescence light energy
March 7, 2019
LumiHeal was granted the Canadian Medical Device License (MDL) for “the management of post-surgical closed wounds and to help in the prevention of hypertrophic scars and post-surgical wound complications in patients 18 years and older”
March 1, 2019
Fluorescence Biomodulation has been added to various sections in the Journal of Wound Care’s 2019 peer-reviewed International Consensus Document – Implementing TIMERS: the race against hard-to-heal wounds
February 26-27, 2019
Animal Health Investment Europe – London, England
February 2-7, 2019
SPIE Photonics West – San Francisco, USA
January 30, 2019
LumiHeal Newsletter – Updates On Our Lead Wound Care Product
January 20-22, 2019
Journées Cicatrisations – Paris, France
January 7-10, 2019
J.P. Morgan Healthcare Conference – San Francisco, USA
November 5-7, 2018
Wounds UK – Harrogate, UK
November 4, 2018
Publication in the peer-reviewed Journal of Wound Care – Evaluation of fluorescence biomodulation in the real-life management of chronic wounds: The EUREKA trial
September 24-26, 2018
The MedTech Conference – Philadelphia, USA
September 12-14, 2018
The European Pressure Ulcer Advisory Panel – Rome, Italy
July 2, 2018
Klox announces positive top-line results from a pivotal study of Phovia™ for the management of Canine Deep Pyoderma – See Full Press Release
June 13-14, 2018
Wound Care from Innovations to Clinical Trials (WCICT) – Edinburgh, United Kingdom
June 4-7, 2018
BIO International Convention – Boston, USA
May 9-11, 2018
The European Wound Management Association (EWMA) – Krakow, Poland
May 2-3, 2018
The Bloom Burton & Co. Healthcare Investor Conference – Toronto, Canada
April 25-29, 2018
The Symposium on Advanced Wound Care Spring (SAWC) – Charlotte, North Carolina